Table 1.
Characteristics of Patients Receiving IP/IV or IV Chemotherapy at NCCN Centers (2006-2012)
| Characteristic | No. (%) | Unadjusted |
Adjusted |
|||
|---|---|---|---|---|---|---|
| Receiving IP/IV Chemotherapy (%) | P | Odds Ratio | 95% CI | P | ||
| Overall | 498 (100) | 41 | ||||
| Age, years | < .001 | < .001 | ||||
| 18-54 | 144 (29) | 49 | Reference | — | ||
| 55-64 | 185 (37) | 45 | 0.81 | 0.48 to 1.39 | ||
| 65-74 | 117 (23) | 37 | 0.46 | 0.25 to 0.86 | ||
| > 74 | 52 (10) | 12 | 0.11 | 0.04 to 0.32 | ||
| Race | .19 | .70 | ||||
| White | 456 (92) | 41 | Reference | — | ||
| Non-white | 42 (8) | 31 | 0.85 | 0.36 to 1.99 | ||
| Ethnicity | .88 | .60 | ||||
| Non-Hispanic | 480 (96) | 41 | Reference | — | ||
| Hispanic | 18 (4) | 39 | 0.71 | 0.20 to 2.52 | ||
| Income* | .32 | .16 | ||||
| 1 (lowest) | 125 (25) | 34 | Reference | — | ||
| 2 | 125 (25) | 39 | 1.86 | 0.99 to 3.48 | ||
| 3 | 124 (25) | 44 | 1.86 | 0.99 to 3.52 | ||
| 4 (highest) | 124 (25) | 44 | 1.78 | 0.92 to 3.45 | ||
| GOG performance status | .20 | .36 | ||||
| 0 | 350 (70) | 41 | Reference | — | ||
| 1-2 | 70 (14) | 33 | 0.88 | 0.41 to 1.88 | ||
| Unknown | 78 (16) | 47 | 0.58 | 0.27 to 1.23 | ||
| Charlson score | < .001 | .002 | ||||
| 0 | 381 (77) | 45 | Reference | — | ||
| 1 | 46 (9) | 15 | 0.20 | 0.08 to 0.53 | ||
| 2+ | 71 (14) | 31 | 0.55 | 0.29 to 1.06 | ||
| Primary site | .05 | .42 | ||||
| Ovarian | 405 (81) | 42 | Reference | — | ||
| Fallopian | 42 (8) | 48 | 1.50 | 0.68 to 3.31 | ||
| Peritoneal | 51 (10) | 25 | 0.73 | 0.33 to 1.63 | ||
| Stage | .55 | .78 | ||||
| III† | 14 (3) | 43 | 0.72 | 0.18 to 2.81 | ||
| IIIA | 30 (6) | 30 | 0.63 | 0.23 to 1.71 | ||
| IIIB | 52 (10) | 46 | 1.08 | 0.50 to 2.30 | ||
| IIIC | 402 (81) | 41 | Reference | — | ||
| Histology | .10 | .16 | ||||
| Serous | 378 (76) | 43 | Reference | — | ||
| Nonserous | 120 (24) | 34 | 0.68 | 0.39, 1.17 | ||
| Grade | .22 | .30 | ||||
| I-II‡ | 97 (19) | 35 | Reference | — | ||
| III | 401 (81) | 42 | 1.37 | 0.75 to 2.49 | ||
| Residual disease | .64 | .61 | ||||
| None | 183 (37) | 42 | Reference | — | ||
| ≤ 1 cm | 145 (29) | 42 | 0.75 | 0.42 to 1.35 | ||
| Optimal | 170 (34) | 38 | 0.93 | 0.53 to 1.64 | ||
| Institution | < .001 | < .001 | ||||
| 1 | § | 67 | 3.30 | 1.15 to 9.47 | ||
| 2 | § | 63 | 1.44 | 0.66 to 3.13 | ||
| 3 | § | 4 | 0.03 | 0.01 to 0.13 | ||
| 4 | § | 20 | 0.20 | 0.08 to 0.46 | ||
| 5 | § | 31 | 0.31 | 0.13 to 0.71 | ||
| 6 | § | 49 | Reference | — | ||
| Year of surgery | .12 | .07 | ||||
| 2006 | 85 (17) | 33 | Reference | — | ||
| 2007-2008 | 159 (32) | 48 | 1.89 | 0.98 to 3.63 | ||
| 2009-2010 | 164 (33) | 38 | 0.96 | 0.49 to 1.89 | ||
| 2011-2012 | 90 (18) | 39 | 1.03 | 0.48 to 2.24 | ||
Abbreviations: GOG, Gynecologic Oncology Group; IP, intraperitoneal; IV, intravenous; NCCN, National Comprehensive Cancer Network.
*
Derived from the Census 2000 data linked to patient by zip code. Income was unknown for 21 patients (4%), and was imputed on the basis of the median income of patients separately by institution.
†
Includes 14 patients with unknown substage.
‡
Includes 21 patients with unknown grade.
§
Absolute numbers are suppressed to protect the identity of individual institutions.